Compared with WT controls, CMKLR1−/− mice had significantly reduced clinical signs to the dihydrotestosterone-induced polycystic ovary syndrome (Tang et al., 2016), experimental autoimmune encephalomyelitis (Graham et al., 2009), and chronic obstructive pulmonary disease (Demoor et al., 2011). Here, CMKLR1 is linked to polycystic ovary syndrome.